Pembrolizumab biosimilar - Samsung Bioepis
Alternative Names: SB-27Latest Information Update: 09 Apr 2024
At a glance
- Originator Samsung Bioepis
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 12 Mar 2024 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, First-line therapy) in Spain, Spain, Romania, India, Georgia (IV) (NCT06348199)
- 28 Feb 2024 Pembrolizumab biosimilar - Samsung Bioepis is available for licensing as of 28 Feb 2024 (Samsung Bioepis pipeline, February 2024)
- 16 Jan 2024 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Adjuvant therapy) in South Korea (IV) (NCT06268613)